ME/CFS AUSTRALIA (SA) INC Registered Charity 698 Mailing address: GPO Box 383, Adelaide, South Australia 5001 Office: 266 Port Road, Hindmarsh, South Australia 5007 Ph: (08) 8346 3237 ('834 MECFS') Office Hours: Wednesdays, 10am-3pm Support Line: (Mondays and Thursdays, 10am-3pm) Ph: (08) 8346 3237 SA country callers: Ph: 1300 128 339 (local call)
ME/CFS Australia (SA) Inc supports the needs of sufferers of Myalgic Encephalomyelitis, Chronic Fatigue Syndrome and related illnesses. We do this by providing services and information to members.
Disclaimer ME/CFS Australia (SA) Inc aims to keep members informed of the various research projects, diets, medications, therapies etc. All communication, both verbal and written, is merely to disseminate information and not to make recommendations or directives. Unless otherwise stated, the views expressed on this Web site are not necessarily the official views of the Society or its Committee and are not simply an endorsement of products or services. |
|
|||||||||||||
Phoenix Rising: February 2008Wednesday 16 April 2008
You can subscribe to the newsletter as well as download each issue. The latest offering from Phoenix Rising is the February 2008 edition:
Here is Cort’s introduction: Welcome to the February edition of Phoenix Rising. In this edition (with a new format) we take a close look at an important event: the first theory paper on CFS by a senior Centers for Disease Control and Prevention researcher that I’m aware of. This paper suggests the CDC, for the first time, is confident enough about what they know about CFS to take a stab at explaining it. Given the CDC’s clout in the small ME/CFS research world this paper is worth looking at closely. We also take advantage of the Dr. Reeve’s testimony during the last CFS Federal Advisory Committee Meeting to take a broad look at the most prominent CFS research program in existence. We’ll roll into the big month of May with Dr. Friedman’s three-part interview; in Part I, Dr. Friedman, a past CFSAC member bluntly talks about the federal response to ME/CFS; in Part II he focuses on the research situation in CFS, in Part III: he talks about our progress in advocacy and what needs to be done. Happy reading! Cort
|
||||||||||||||